VANCOUVER, British Columbia, March 24, 2011 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) announces it is presenting Friday, March 25, 2011 a poster titled "A new Carrier for Delivery of Therapeutic Compounds Across the BBB for the Treatment of Brain Diseases" at the 17 th annual Blood-Brain Barrier Consortium meeting held in collaboration with the International Brain Barriers Society (IBBS) being held in Stevenson, Washington.
The poster provides a summary of key scientific accomplishments achieved by the Company, including results from its recent collaborations with the University of British Columbia and the National Research Council of Canada. The data from these collaborations further demonstrated that conjugations developed under the biOasis Transcend program cross the blood-brain barrier more efficiently than is possible with other approaches, that the conjugates enter the brain tissue, and that a conjugate incorporating doxorubicin increased survival time in animal models of glioblastoma, the most common and most aggressive type of primary brain tumor in humans. A copy of the poster can be downloaded from our web site at www.bioasis.ca .
"We are pleased to participate in this meeting, both as a corporate sponsor and by presenting a poster," stated Dr. Reinhard Gabathuler. "The IBBS meeting provides the opportunity to share and discuss our findings with thought leaders in the blood-brain barrier research community."The IBBS is an international scientific and educational nonprofit organization that: encourages, promotes and advocates scientific and clinical research on the biological barriers in the central nervous system (CNS); accumulates information about barriers in the CNS and promotes its dissemination to scientists, physicians, patients, policy makers, public and private funding agencies and other concerned parties, and; educates the general public and medical profession about the existence, diagnosis and treatment of disorders involving the barriers of the CNS.